Li-Ming Gan

My speciality is in clinical cardiovascular diagnostics and I actively run academic research in the field of cardiovascular phenotyping of patients with ischemic heart disease and heart failure, as well as the development and validation of preclinical translational disease models. I am also Chief Physician at the Department of Cardiology at Sahlgrenska University Hospital and since 2009, I’ve held a professorship in translational cardiovascular research and drug discovery at Sahlgrenska Academy, Sahlgrenska University Hospital in Gothenburg, Sweden.

Since joining AstraZeneca more than 20 years ago, I’ve been involved in preclinical and clinical development of novel therapeutics using traditional small molecule approaches. I’m also involved in exploring non-small molecule modalities, including peptide, antibody, ASO, cell therapy, as well as mRNA, where I led the world´s first trial in humans using an mRNA platform.

Between 2007-2011, I was responsible for the atherosclerosis and heart failure pipeline and between 2011-2013,I worked as a Translational Science Director to help bridge the early projects into the human setting. 

In 2013, I was appointed Senior Director Physician in early clinical research unit and I’m responsible for Phase I and II clinical programs within the cardiovascular area. Since 2019, as Vice President and Head of Early Clinical Development in Early CVRM, I am accountable for global early clinical studies in cardiovascular, heart failure, diabetes, NASH and renal diseases. To date, together with my teams, we have brought a number of novel projects from target ideas through to preclinical translational research and into clinical proof of concept testing in the CVRM area.